Septerna Initiates Phase 1 Clinical Trial for SEP-479 in Hypoparathyroidism
Septerna Initiates Phase 1 Clinical Trial for SEP-479, an Oral PTH1R Agonist Targeting Hypoparathyroidism
SOUTH SAN FRANCISCO, Calif. – April 13, 2026 – Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering G protein-coupled receptor (GPCR) drug discovery, has announced a significant milestone with the initiation of its Phase 1 clinical trial for SEP-479. This potent oral small molecule is a parathyroid hormone 1 receptor (PTH1R) agonist being developed for the treatment of hypoparathyroidism, a rare and debilitating endocrine disorder.
Key Points of the Announcement
- First-in-human dosing: The first participants have been dosed in the Phase 1 clinical trial of SEP-479, marking the transition from preclinical to clinical development.
- Trial design: The Phase 1 study is randomized and placebo-controlled, enrolling up to 150 healthy adult volunteers. It consists of single-ascending dose (SAD) and multiple-ascending dose (MAD) cohorts.
- Endpoints: The primary objectives are to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SEP-479. Secondary and exploratory endpoints include changes in endogenous PTH, serum calcium, and other biomarkers.
- Timeline: Initial data from this trial are anticipated in late 2026 or early 2027.
- Preclinical results: SEP-479 demonstrated activity comparable to PTH peptides in cell-based and in vivo models, normalized serum calcium in a rat model, and showed efficacy in non-human primate studies, with a favorable safety profile over 28-day toxicology studies in rats, dogs, and primates.
Potential Impact and Shareholder Considerations
This announcement is potentially highly price-sensitive for shareholders and could impact Septerna’s share value for several reasons:
-
Addressing a Major Unmet Need: Hypoparathyroidism is a lifelong condition managed with frequent, high-dose calcium/vitamin D supplements or daily PTH injections, both of which are burdensome and have limitations. SEP-479 aims to offer a once-daily oral alternative, which could dramatically improve patient quality of life.
-
Differentiation from Competitors: If successful, SEP-479 would be the first oral small molecule PTH1R agonist, potentially giving Septerna a strong competitive advantage in a market with limited innovation and high unmet needs.
-
Clinical Validation of Platform: Positive outcomes from SEP-479’s trial may not only validate this asset but also Septerna’s proprietary Native Complex Platform® for GPCR drug discovery, broadening the company’s credibility and pipeline potential.
-
Milestone Timeline: Investors should note that meaningful clinical data is not expected until late 2026 or early 2027, and there are typical clinical development risks regarding safety, efficacy, and trial execution.
-
Forward-Looking Statements and Risks: The company emphasizes that while preclinical results are promising, there is no guarantee they will translate into clinical success. Risks include unforeseen safety, PK, or PD findings, delays in trial enrollment, and intellectual property uncertainties.
About SEP-479 and Hypoparathyroidism
SEP-479 is designed as a potent oral PTH1R agonist. In preclinical studies, it matched PTH peptides in efficacy, normalized serum calcium in animal models, and showed a good safety profile in 28-day GLP toxicology studies across multiple species. Hypoparathyroidism, the target indication, is marked by PTH deficiency leading to muscle cramps, fatigue, cognitive dysfunction, and potentially life-threatening complications.
Current treatments are limited; high-dose supplements and daily PTH injections are standard. SEP-479, as a once-daily oral therapy, has the potential to become a game-changer for patient management and adherence.
About Septerna
Septerna is a clinical-stage biotech company leveraging its Native Complex Platform® for GPCR drug discovery and development. The company’s pipeline includes novel oral small molecule therapies targeting endocrinology, immunology, inflammation, metabolic diseases, and other therapeutic areas, both independently and with partners.
Investor and Media Contacts
Disclaimer: This article includes forward-looking statements based on current information and management expectations as of the date of publication. These statements are subject to risks and uncertainties that may cause actual results to differ materially, including clinical trial outcomes, regulatory developments, intellectual property protection, and general market conditions. Investors should refer to Septerna’s filings with the SEC for a detailed discussion of risk factors. This article is for informational purposes only and does not constitute investment advice.
View Septerna, Inc. Historical chart here
